A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Bayer
Information provided by (Responsible Party):
Jose Lutzky, Mt. Sinai Medical Center, Miami
ClinicalTrials.gov Identifier:
NCT00483301
First received: May 30, 2007
Last updated: May 2, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2009
  Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)